TrialJournal of acquired immune deficiency syndromes (1999)2010

HIV/Hepatitis C virus-coinfected virologic responders to pegylated interferon and ribavirin therapy more frequently incur interferon-related adverse events than nonresponders do.

Anu Osinusi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.